LumiThera said today it inked a distribution deal with Nikon (TYO:7731) subsidiary Optos to distribute its Valeda light delivery system intended for use in treating dry age-related macular degeneration. The deal will position Optos as the exclusive distributor of the device in 12 European countries, the Seattle-based company said. The device has already won CE Mark approval in the […]
European semiconductor manufacturer ASML and its strategic partner Carl Zeiss (ETR:AFX) today filed a patent infringement countersuit against Nikon (TYO:7731) in response to legal action taken by Nikon against the companies. The suits involve semiconductor manufacturing equipment, flat panel display manufacturing equipment and digital cameras. On Monday, Nikon filed its own patent case against ASML and Zeiss […]
Nikon (TYO:7731) subsidiary Optos and Google (NSDQ:GOOG) unit Verily inked a deal this week to develop technologies for machine learning-enabled retinal imaging. The deal calls for the companies will collaborate on improving the screening for diabetic retinopathy and diabetic macular edema, both among the leading causes of blindness worldwide. The program combines Nikon’s leadership in optical engineering and precision […]
Silicon Valley-based 3D printing company Carbon said today that it raised $81 million in a new funding round it plans to use for its medical device and auto part printing business. Get the full story at our sister site, Medical Design & Outsourcing.
March 2, 2015 by Brad Perriello
(Reuters) – Nikon, the 98-year-old Japanese company best known for its cameras, has agreed to buy British retinal imaging firm Optos for 259.3 million pounds ($400 million) as it moves into the medical sector.
Nikon has previously said it intended to enter the medical sector to leverage its optical technologies and the Japanese group sees buying Optos as an important step in that long-term growth plan.
Kazuo Ushida, president of Nikon, said the company would expand the medical business further in the future.
Chinese regulators slapped a string of contact lens and eyeglass makers with more than $3 million (19 million yuan) in fines after accusing them of violating the country’s anti-trust laws.
CAZ Investments raised a nearly $29 million funding round it plans to use to back medical companies that already have products on the market.
The Houston-based asset management firm reeled in $28.7 million from 61 unnamed investors, according to a regulatory filing.
CAZ Investments chairman Christopher Zook said the firm plans to use the cash to invest in commercialized companies.